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Objectives: We evaluated early and late results of allograft replacement to treat infrarenal aortic graft infection in a large
number of patients and compared the results in patients who received fresh allografts versus patients who received
cryopreserved allografts.
Methods: From 1988 to 2002 we operated on 179 consecutive patients (mean age, 64.6  9.0 years; 88.8% men). One
hundred twenty-five patients (69.8%) had primary graft infections, and 54 patients (30.2%) had secondary aortoenteric
fistulas (AEFs). Fresh allografts were used in 111 patients (62.0%) until 1996, and cryopreserved allografts were used in
68 patients (38.0%) thereafter.
Results: Early postoperative mortality was 20.1% (36 patients), including four (2.2%) allograft-related deaths from
rupture of the allograft (recurrent AEF, n 3), all in patients with fresh allografts. Thirty-two deaths were not allograft
related. Significant risk factors for early mortality were septic shock (P < .001), presence of AEF (P  .04), emergency
operation (P  .003), emergency allograft replacement (P  .0075), surgical complication (P  .003) or medical
complication (P < .0001), and need for repeat operation (P  .04). There were five (2.8%) nonlethal allograft
complications (rupture, n  2; thromboses, which were successfully treated at repeat operation, n  2; and amputation,
n 1), all in patients with fresh allografts. Four patients (2.2%) were lost to follow-up. Mean follow-up was 46.0 42.1
months (range, 1-148 months). Late mortality was 25.9% (37 patients). There were three (2.1%) allograft-related late
deaths from rupture of the allograft, at 9, 10, and 27 months, respectively, all in patients with fresh allografts. Actuarial
survival was 73.2%  6.8% at 1 year, 55.0%  8.8% at 5 years, and 49.4%  9.6% at 7 years. Late nonlethal aortic events
occurred in 10 patients (7.2%; occlusion, n  4; dilatation < 4 cm, n  5; aneurysm, n  1), at a mean of 28.3  28.2
months, all but two in patients with fresh allografts. The only significant risk factor for late aortic events was use of an
allograft obtained from the descending thoracic aorta (P  .03). Actuarial freedom from late aortic events was 96.6% 
3.4% at 1 year, 89.3%  6.6% at 3 years, and 89.3%  6.6% at 5 years. There were 63 late, mostly occlusive, iliofemoral
events, which occurred at a mean of 34.9  33.7 months in 38 patients (26.6%), 28 of whom (73.7%) had received fresh
allografts. The only significant risk factor for late iliofemoral events was use of fresh allografts versus cryopreserved
allografts (P .03). Actuarial freedom from late iliofemoral events was 84.6% 7.0% at 1 year, 72.5% 9.0% at 3 years,
and 66.4%  10.2% at 5 years.
Conclusions: Early and long-term results of allograft replacement are at least similar to those of other methods to manage
infrarenal aortic graft infections. Rare specific complications include early or late allograft rupture and late aortic
dilatation. The more frequent late iliofemoral complications may be easily managed through the groin. These complica-
tions are significantly reduced by using cryopreserved allografts rather than fresh allografts and by not using allografts
obtained from the descending thoracic aorta. (J Vasc Surg 2004;39:1009-17.)Although arterial allografts were used extensively for
infrarenal aortic replacement during the first decade of
reconstructive arterial surgery,1-4 they were abandoned in
the early 1960s because of difficulties with procurement
and preservation, late deterioration, and availability of suit-
able arterial prosthetic grafts. In 1991 we reintroduced the
use of arterial allografts for surgical management of infra-
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doi:10.1016/j.jvs.2003.12.040renal aortic prosthetic graft infection.5 Since then, all pa-
tients seen at the Vascular Surgery Department, Pitie´-
Salpeˆtrie`re University Hospital in Paris, France, at first
received fresh allografts, and since August 1996 cryopre-
served allografts. The purpose of this study was to report
our present experience in 179 patients and to compare the
results obtained with fresh allografts versus cryopreserved
allografts.
PATIENTS AND METHODS
Population. From October 8, 1988, to November
30, 2002, all patients with infected infrarenal aortic pros-
thetic grafts seen at the Department of Vascular Surgery,
Pitie´-Salpeˆtrie`re University Hospital in Paris, France, un-
derwent complete resection of the prosthesis, followed by
in situ allograft replacement.
There were 179 consecutive patients, 159 men (88.8%)
and 20 women (11.2%), with a mean age of 64.6  9.0
years (range, 29-82 years). Fifty-four patients (30.2%) had1009
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mary graft infections. Twenty-three patients (12.8%) had
undergone initial operation in our center, and 156 patients
(87.2%) were referred to us after an operation performed
elsewhere. The initial operation was performed to treat
atherosclerotic aortoiliac occlusive disease in 124 patients
(69.3%), degenerative aortic aneurysm disease in 53 pa-
tients (29.6%), blunt aortic trauma in 1 patient (1.1%), and
Takayasu arteritis in 1 patient (1.1%).
Mean interval between the initial operation and allo-
graft replacement was 6.1 5.4 years (1 month–24 years).
Sixty-eight patients (38.0%) underwent no repeat opera-
tion between the initial operation and allograft replace-
ment, whereas 111 patients (62.0%) underwent a mean of
2.8  2.1 repeat operations (range, 1-16).
Clinical presentation. Sepsis, including fever and leu-
kocytosis, was present in 125 patients (69.8%), an inguinal
or retroperitoneal abcess in 67 patients (37.4%), draining
inguinal sinus in 53 patients (29.6%), graft thrombosis in
44 patients (24.6%), femoral false aneurysm in 32 patients
(17.9%), gastrointestinal bleeding in 24 patients (13.4%),
aortic false aneurysm in 21 patients (11.7%), and septic
emboli in 6 patients (3.4%). There were 58 secondary
aortoenteric fistulas in 54 patients. The duodenum was
involved in 40 patients, the small intestine in 12 patients,
and the colon in 6 patients.
Fig 1. Postoperative aortogram shows bilateral hypogastric revas-
cularization in a patient who underwent allograft replacement to
treat infrarenal aortic graft infection.Procurement and preservation of allografts. Al-
lografts were harvested from brain-dead donors as part of a
program to retrieve multiorgan transplant tissue. Bacteriol-
ogy and virology tests were routinely performed in donors.
Matching of blood and tissue compatibility between recip-
ient and donor was not attempted. The entire length of the
descending thoracic aorta, aortic bifurcation, and iliac and
femoral arteries was obtained. Small collateral branches
were transected a few millimeters distal to their origin, to
facilitate later ligation or suture. Hypogastric and deep
femoral arteries were transected 2 to 3 cm distal to their
origins, to enable revascularization of the corresponding
arteries in the recipient.
Until August 1996, fresh allografts, stored from 48
hours to 37 days (mean, 13.0 8.6 days) at 4°C in 500 mL
of a preservation medium containing heparin and antibiotic
agents,6 were used in 111 patients (62.0%). After August
1996, because of changes in French health regulations, 68
patients (38.0%) received cryopreserved allografts prepared
by the Tissue Bank of Paris Hospitals.
A segment of descending thoracic aorta was used in 10
patients (5.6%), a segment of infrarenal aorta and various
lengths of the iliac and femoral arteries in 140 patients
(78.2%), and both in 29 patients (16.2%).
Allograft implantation. A median laparotomy was
routinely used. Infrarenal aortic clamping was feasible in
111 patients (62.0%), whereas 68 patients (38.0%) had
interrenal (n  11), suprarenal (n  25), supraceliac (n 
29), or thoracic (n 3) aortic clamping. Complete removal
of all prosthetic material, whether or not grossly infected,
was routine. The aortic stump and periprosthetic tissues
were aggressively debrided to obtain macroscopically nor-
mal tissues.
The allograft was implanted in situ with polypropylene
running sutures for proximal and distal anastomoses. It was
tunneled to the distal anastomotic site by way of either the
previous pathway or a new pathway in close proximity to
the previous pathway. There were 30 entirely intra-abdom-
inal allograft replacements (16.8%), whereas 149 (83.2%)
included at least one femoral anastomosis. The proximal
allograft anastomosis was end-to-end in 151 patients
(84.4%). Retroperitoneal and inguinal drainage was rou-
tine. The skin incisions were loosely approximated to avert
superficial abscesses. In case of major fibrosis or infection of
the inguinal region, the skin was left open, and the graft was
covered with a myoplasty using the sartorius muscle.
Associated procedures. Ten patients (5.6 %) under-
went associated reconstruction of the renal arteries (unilat-
eral in 8 patients, bilateral in 2 patients). Seventeen patients
(9.5%) underwent associated reconstruction of visceral ar-
teries (inferior mesenteric artery in 10 patients, superior
mesenteric artery in 6 patients, celiac and superior mesen-
teric arteries in 1 patient). Forty-four patients (24.6%)
underwent associated reconstruction of hypogastric arteries
(unilateral in 32 patients, bilateral in 12 patients; Fig 1).
Twenty-six patients (20.1 %) underwent associated recon-
struction of lower limb arteries, including femoropopliteal
bypass in 23 patients (bilateral in 3 patients) and femoro-
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material. Three patients (1.7 %) with tight stenosis of an
internal carotid artery underwent associated carotid
endarterectomy.
The 40 duodenal fistulas were treated with suturing in
36 patients and resection-anastomosis in 4 patients. A
feeding jejunostomy was performed in 23 patients (57.5%).
The 12 intestinal fistulas were treated with suturing in 7
patients and resection-anastomosis in 5 patients. The six
colonic fistulas were treated with colectomy in 5 patients
(with proximal colostomy in 3 patients) and exteriorization
in 1 patient.
Omentoplasty was performed in 104 patients (58.1 %)
whenever technically feasible. Cholecystectomy was per-
formed in 18 patients, ureteral repair or lysis in 6 patients,
appendectomy in 5 patients, colectomy to treat colonic
ischemia in 4 patients, nephrectomy in 3 patients, and
splenectomy in 2 patients. Six patients underwent concom-
itant major amputation because of septic arthritis or estab-
lished gangrene.
Bacteriology. Identification of the responsible organ-
ism or organisms was obtained either preoperatively from
blood cultures, draining sinuses, or direct or computed
tomography (CT)–guided needle aspiration or intraopera-
tively by culturing all available material, including peripros-
thetic fluid or tissue and part of the infected prosthetic
graft. Identified organisms in 149 patients (83.2%) are
shown in Table I (online only). One organism was identi-
fied in 68 patients (45.6%), two organisms in 40 patients
(26.9%), three organisms in 31 patients (20.8%), and more
than three organisms in 10 patients (6.7%). A mean of 1.92
 1.06 organisms was identified in the overall series. The
most prevalent organisms were Staphylococcus, Enterococ-
cus, Escherichia coli, Pseudomonas aeruginosa, and fungi.
No organisms were identified in 30 patients (16.8%). This,
together with the high incidence of fungal infection, prob-
ably attests to the long-standing preoperative antibiotic
therapy in a significant number of patients.
All patients received broad-spectrum antibiotic agents
before and during the operation, and then selective antibi-
otic agents after the responsible organisms were identified.
Administration of antibiotic agents was continued for at
least 6 weeks. No patients received long-term or indefinite
antibiotic therapy.
Follow-up. All surviving patients underwent digital
substraction aortography before or soon after discharge.
Routine late follow-up included clinical examination and
duplex scanning at 3-month intervals during the first year,
and yearly thereafter. Late CT or aortography was per-
formed depending on the results of duplex scanning.
RESULTS
Early results
Mortality. Thirty-six patients (20.1%) died during the
early postoperative period or during hospitalization (Table
II, online only). There were four allograft-related deaths
(2.2%), from allograft rupture, including three recurrentaortoenteric fistulas. All of these patients had been operated
on to treat aortoenteric fistulas and had received fresh
allografts. Thirty-two deaths were not allograft related, but
were due to septic shock in 12 patients, myocardial infarc-
tion in 5 patients, respiratory complications in 4 patients,
recurrent duodenal fistula (without aortoenteric fistula) in
2 patients; coagulopathy, multiorgan failure, and intestinal
infarction in 2 patients each; and adrenal insufficiency and
acute pancreatitis in one patient each.
Univariate analysis identified seven risk factors for early
mortality: presence of aortoenteric fistula (P .04), occur-
rence of intraoperative or postoperative septic shock (P 
.0001), emergency operation (P  .003), emergency allo-
graft replacement (P  .007), surgical complication (P 
.004) or medical complication (P .0001), and need for a
repeat operation (P  .04). The difference between fresh
allografts and cryopreserved allografts approached statisti-
cal significance (P  .07).
Surgical complications. Forty-two surgical complica-
tions, either lethal or nonlethal, occurred in 36 patients
(20.1%; Table III, online only). There were eight allograft-
related early surgical complications, including three recur-
rent aortoenteric fistulas (two repeat operations, three
deaths), three allograft ruptures without aortoenteric fis-
tula (three repeat operations, one death), and two allograft
thromboses (two repeat operations, no deaths). All of these
patients had received fresh allografts. The most significant
non-allograft-related surgical complications were ischemic
colitis in six patients (six repeat operations, three deaths)
and recurrent duodenal fistula without aortoenteric fistula
in two patients (two repeat operations, two deaths). One
patient (0.5%) underwent a major amputation after throm-
bosis of an associated femoropopliteal bypass and failure of
thrombectomy.
Medical complications. Medical complications, ei-
ther lethal or nonlethal, occurred in 81 patients (45.3%).
The most significant medical complications were respira-
tory complications in 49 patients (four deaths), septic shock
in 44 patients (12 deaths), acute renal failure (creatinine
concentration 200 mol/L) in 34 patients (no deaths),
and myocardial infarction in 12 patients (five deaths).
Late results
Follow-up. Among the 143 survivors to the postop-
erative period, 4 patients (2.8%) were lost to follow-up at 6,
20, 24, and 46 months, respectively. One hundred thirty-
nine patients (97.2%) were followed up until their death or
the last 3 months of 2002. Mean follow-up was 46.0 
42.1 months for fresh allografts and 1 to 148 months
(median, 34 months) for cryopreserved allografts.
Mortality. There were 37 late deaths (25.9%). Three
deaths (2.1%) were allograft related, from rupture of the
allograft at 9, 10, and 27 months, respectively. One of these
ruptures was caused by persistent or recurrent infection; the
other two were apparently mechanical in origin. Two late
ruptures occurred in patients who received fresh allografts,
and one occurred in a patient who received a cryopreserved
allograft. There were 34 non-allograft-related late deaths.
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were cancer (11 patients) and myocardial infarction (8
patients). With the Kaplan-Meier method, and including
early deaths, the probability for late survival after allograft
replacement to treat infrarenal aortic prosthetic infection
was 73.2% 6.8% at 1 year, 63.0% 8.0% at 3 years, 55.0%
 8.8% at 5 years, and 49.4%  9.6% at 7 years (Fig 2).
Aortic events. There were 12 late aortic events in 12
patients (8.4%; Table IV, online only). Four thromboses
Fig 3. Computed tomography scan demonstrates mild
months postoperatively.
Fig 2. Cumulative Kaplan-Meier curve shows early and l
infrarenal aortic graft infection.occurred at 2, 4, 5, and 61 months, respectively. These
were in two patients with fresh allografts and two patients
with cryopreserved allografts. The four patients underwent
successful repeat operation (repeat allografting, n  2;
thrombectomy, n 1; axillobifemoral bypass, n 1). Five
dilatations involving the aortic portion of the allograft,
defined as aortic diameter less than 40 mm (Fig 3), were
diagnosed at 14, 14, 28, 30, and 35 months, respectively.
Three patients died of unrelated causes without repeat
tation of the aortic allograft, with mural thrombus, 35
rvival in 179 patients after allograft replacement to treatdilaate su
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with periodic CT. All dilatations occurred in patients who
received fresh allografts, including four allografts obtained
from the descending thoracic aorta. In one patient (0.7% of
the entire series) an aneurysm developed, defined as aortic
diameter greater than 40 mm, and was diagnosed at 90
months. The patient underwent repeat operation with an
endovascular prosthetic graft, and then a surgical conver-
sion to treat type I endoleak. He had received a fresh
allograft obtained from the descending thoracic aorta. Fi-
nally, there were two late lethal aortic ruptures, at 10 and
27 months, respectively. Both patients had received fresh
allografts, including one that was obtained from the de-
scending thoracic aorta.
Univariate analysis showed that the use of an allograft
obtained from the descending thoracic aorta is a significant
risk factor for late aortic events (P  .03). The use of fresh
allografts versus cryopreserved allografts almost reached
significance (P .07). With the Kaplan-Meier method, and
including early aortic events, the probability of freedom
from aortic events was 96.6%  3.4% at 1 year, 89.3% 
6.6% at 3 years, 89.3% 6.6% at 5 years, and 87.3% 7.4%
at 7 years (Fig 4).
Iliofemoral events. There were 63 late iliofemoral
events in 38 patients (26.6%; Table IV, online only). These
included 42 occlusive lesions, diagnosed at 2 to 89 months
(mean, 25.8 months; Fig 5),; 20 dilatations or aneurysms,
diagnosed at 2 to 113 months (mean, 52.7 months); and
one recurrent infection, diagnosed at 62 months. Twenty-
eight patients had received fresh allografts, and 10 had
received cryopreserved allografts. Among these 38 patients,
30 (78.9%) have undergone repeat operation at least once.
A total of 59 repeat interventions were performed, includ-
ing 26 prosthetic (polytetrafluoroethylene) graft replace-
Fig 4. Cumulative Kaplan-Meier curve shows freedom fr
aortic graft infection.ments, 14 repeat allograft replacements, 8 autogenous vein
replacements, 6 endovascular procedures, and 5
thrombectomies.
Univariate analysis showed that the use of fresh allo-
grafts versus cryopreserved allografts was a significant factor
for late iliofemoral events (P .03) (Table V, online only,).
With the Kaplan-Meier method, the probability of freedom
from iliofemoral events was 84.6% 7.0% at 1 year, 72.5%
 9.0% at 3 years, and 66.4%  10.2% at 5 years (Fig 6).
Patency and freedom from dilatation. Relevant data
are provided in Table VI (online only).
DISCUSSION
Our reasons for embarking on allograft replacement to
treat infrarenal aortic graft infection were as follows. First
was dissatisfaction with conventional treatment, that is,
graft removal and axillofemoral bypass grafting, in terms of
both mortality and anatomic durability. Although contem-
porary series report significant improvement in mortali-
ty,7,8 axillofemoral bypass grafting to treat infectious le-
sions is still laden with significant rates of reinfection and
occlusion.9 The second reason included low applicability of
in situ repair with autogenous arterial material,10 duration
of operation for harvesting autogenous femoral veins,11
and presumed high risk for reinfection after in situ replace-
ment with prosthetic grafts, despite occasional reports of
satisfactory results.12,13 Third was the experience of cardiac
surgeons with allograft replacement of aortic root in pa-
tients with infective endocarditis.14,15 Fourth, there is ex-
perimental evidence of resistance to infection of fresh vas-
cular allografts.16,17 Fifth was availability of arterial
allografts harvested from brain-dead donors as part of an
active local multiorgan transplant retrieval program.
ortic events after allograft replacement to treat infrarenalom a
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aortic allografts, our initial intention was to use allografting
as a bridge to late repeat prosthetic grafting18 after the
infection had subsided. Close follow-up of our patients has
shown that allografts fared much better than we expected,
with few indications for secondary prosthetic aortic grafting
despite a significant number of late iliofemoral
events.6,19-21
Allograft replacement, compared with conventional
treatment with graft removal and axillofemoral bypass
grafting,7,8 has the distinct advantages of in situ reconstruc-
tion. It averts complications due to aortic stump disease,
and occlusion or infection of prosthetic extra-anatomic
bypass grafts.9 It enables surgical reconstruction of hypo-
gastric and deep femoral arteries as indicated, reducing the
risk for postoperative ischemic colitis and lower limb isch-
emia. In our entire series there was only one major ampu-
tation after thrombosis of an associated femoropopliteal
bypass. Autologous femoral vein reconstruction also has
the advantage of in situ reconstruction.11 However, al-
though early and late results are good, vein harvesting
significantly increases the duration of operation, and ve-
nous sequelae are not uncommon.
Early rupture of aortic allografts is a rare, though dev-
astating, specific complication of allografting, and the cause
may be either mechanical or infectious.6,19,22-28 Although
“cracking” from cryopreservation and thawing has been
reported both clinically22,25 and experimentally,29 the in-
cidence has been drastically reduced as a result of extensive
Fig 5. Preoperative (A) and postoperative (B) arteriogr
allograft treated with autologous vein replacement.worldwide experimental work on cryopreservation tech-
niques.30-33 Most early ruptures seem to be caused by
infection, which raises the question of allograft infectabil-
ity. Several mechanisms may account for the resistance of
arterial allografts to infection, including the physicochem-
ical properties of the cellular components of allograft, re-
sponses of the host immune system, and, above all, high
antibiotic loading of the allograft.34-36 These mechanisms
are sufficient in most cases to prevent infectious necrosis of
the allograft. However, continuous or recurrent exposure
to an untreated infectious focus or infection with highly
virulent organisms is a logical risk factor for allograft infec-
tion and rupture. This probably accounts, at least in part,
for the significantly higher mortality after allograft replace-
ment to treat secondary aortoenteric fistulas.26-28,37
This study further explores the early and late results of
allografting to treat prosthetic aortic graft infection. Al-
though this is not a randomized study, and follow-up was
longer in patients who received fresh allografts, allograft-
related complications were significantly less frequent in
patients who received cryopreserved allografts than in those
who received fresh allografts. There were no early late
allograft ruptures and no early occlusion in patients with
cryopreserved allografts. This in contrast to the series by
Noel et al,27 who reported five (9%) early cryopreserved
allograft ruptures and five (9%) early graft limb occlusions.
The difference may be explained by differences in cryo-
preservation techniques. Ten of 12 patients (83.3%) with
late aortic events and 28 of 38 patients (73.7%) with late
how late femoral stenosis complicating an aortofemoralams s
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more, we found that the use of an allograft obtained from
the descending thoracic aorta is a significant risk factor for
late aortic events. This is probably due to the lower number
of elastic fibers in the descending thoracic aorta compared
with the abdominal aorta, leading to late mechanical dete-
rioration.
Late deterioration may be immune-mediated32,33,38-40
or mechanical. Aneurysm dilatation, mural thrombosis
(with or without dilatation), calcification, and secondary
atherosclerotic disease have been reported in intermediate
and long-term follow-up of many patients after early clini-
cal experience with aortic allografts.41-46 Our clinical expe-
rience, with a maximum follow-up of 12 years, confirms the
observations of Szilagyi et al.46 Deterioration of arterial
allografts is much more likely to occur in the iliofemoral
portion compared with the aortic portion of the allograft.
This probably reflects major differences in the composition
of the medial layer of the arterial wall. The media of iliac
and femoral arteries is made predominantly of highly anti-
genic smooth muscle cells, accounting for frequent, early
degeneration, probably due to chronic rejection. Con-
versely, the aortic media is made predominantly of elastic
fibers, with few smooth muscle cells. This less potentially
antigenic configuration probably accounts for late mechan-
ical aortic deterioration.
Blood and tissue compatibility,22,31 low-dose immu-
nosuppression therapy,31,33,39 and cell-free allografts47
have been studied experimentally, with little clinical appli-
cation thus far, and no demonstrable clinical benefit. Much
to our surprise, late aortic deterioration has been rather
uncommon and relatively stable, as opposed to the findings
of Szilagyi et al.46 Only one of our patients needed second-
ary aortic replacement, because of aneurysm dilatation,
Fig 6. Cumulative Kaplan-Meier curve shows freedom
infrarenal aortic graft infection.whereas in the series by Szilagyi et al, 9 of 14 patients with
aortic dilatation required repeat operation, and 3 died of
aortic complications. In the recent experience of aortic
allografting, Desgranges et al23 and Julia et al48 reported
the only two other secondary aortic replacements necessary
because of aneurysm dilatation of the allograft. Different
procurement and preservation techniques, influencing
both the mechanical properties and the antigenicity of
allografts, are responsible for such an important difference.
It has been shown experimentally that cryopreservation
protects against both early49 and late31 immune-mediated
arterial allograft dilatation.
However, although our clinical results with cryopre-
served allografts have been encouraging, compared with
those obtained with fresh allografts, our cryopreservation
techniques are probably far from optimal and have not
completely eliminated late deterioration of allografts, espe-
cially in the iliofemoral segment. The use of glutaraldelyde-
treated allografts to avert structural destruction has been
suggested experimentally,50 but has caused massive calcifi-
cation and, to our knowledge, has had no clinical applica-
tion thus far. Although in our experience late iliofemoral
deterioration, including occlusion and aneurysm, has been
much more common than aortic deterioration, it could
usually be treated successfully with local procedures
through the groin, without need for a repeat abdominal
procedure. We hypothesize that most early iliofemoral de-
teriorations were due to chronic rejection, whereas late
deteriorations were usually due to structural degradation of
the medial layer.
CONCLUSION
Early and long-term results of allograft replacement are
at least similar to those of other methods of management of
iliofemoral events after allograft replacement to treatfrom
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clude early or late allograft rupture and late aortic dilata-
tion. The more frequent late iliofemoral complications may
be easily managed through the groin. These complications
are significantly reduced by using cryopreserved allografts
rather than fresh allografts, and not using allografts ob-
tained from the descending thoracic aorta.
REFERENCES
1. Oudot J, Beaconsfield P. Thrombosis of the aortic bifurcation treated
by resection and homograft replacement. Arch Surg 1953;66:365-74.
2. Dubost C, Allary M, Oeconomos N. Resection of an aneurysm of the
abdominal aorta: reestablishment of the continuity by a preserved
human arterial graft, with results after five months. Arch Surg 1952;64:
405-8.
3. DeBakey ME, Creech O Jr. Occlusive disease of the aorta and its
treatment by resection and homograft replacement. Ann Surg 1954;
140:290-310.
4. Szilagyi DE, Overhuise PR, Logrippo GA. Use of chemically sterilized
arterial homografts. Clin Res Proc 1954;2:108-13.
5. Bahnini A, Ruotolo C, Koskas F, Kieffer E. In situ fresh allograft
replacement of an infected aortic prosthetic graft: 18-month follow-up.
J Vasc Surg 1991;14:98-102.
6. Kieffer E, Bahnini A, Koskas F, Ruotolo C, LeBlevec D, Plissonnier D.
In situ allograft replacement of infected infrarenal aortic prosthetic
grafts: results in 43 patients. J Vasc Surg 1993;17:349-56.
7. Seeger JM, Pretus HA, Welborn MB, Ozaki CK, Flynn TC, Huber TS.
Long-term outcome after treatment of aortic graft infection with staged
extra-anatomic bypass grafting and aortic graft removal. J Vasc Surg
2000;32:451-61.
8. Yeager RA, Taylor LM, Moneta GL, Edwards JM, Nicoloff AD, Mc-
Connell DB, et al. Improved results with conventional management of
infrarenal aortic infection. J Vasc Surg 1999;30:76-83.
9. Bacourt F, Koskas F, and Association Universitaire de Recherche en
Chirurgie. Axillo-femoral bypass and aortic exclusion for vascular septic
lesions: a multicenter retrospective study of 98 cases. Ann Vasc Surg
1992;6:119-26.
10. Ehrenfeld WK, Wilbur DG, Olcott CN, Stoney RJ. Autogenous tissue
reconstruction in the management of infected prosthetic grafts. Surgery
1979;85:82-92.
11. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral
reconstruction from superficial femoral-popliteal veins: feasibility and
durability. Am J Surg 1999;178:136-40.
12. Hayes PD, Nasim A, London NJ, Sayers RD, Barrie WW, Bell PR, et al.
In situ replacement of infected aortic grafts with rifampin-bonded
prostheses: the Leicester experience (1992 to 1998). J Vasc Surg
1999;30:92-8.
13. Young RM, Cherry KJ Jr, Davis PM, Gloviczki P, Bower TC, Panneton
JM, et al. The results of in situ prosthetic replacement for infected aortic
grafts. Am J Surg 1999;178:136-40.
14. Donaldson RM, Ross DM. Homograft aortic root replacement for
complicated prosthetic valve endocarditis. Circulation 1984;70(suppl
1):178-81.
15. Pagano D, Allen SM, Bonser RS. Homograft aortic valve and root
replacement for severe destructive native or prosthetic endocarditis. Eur
J Cardiothorac Surg 1994;8:173-6.
16. Moore WS, Swanson RJ, Campagna G, Bean B. The use of fresh tissue
arterial substitutes in infected fields. J Surg Res 1975;18:229-33.
17. Snyder SA, Wheeler JR, Gregory RT, Gayle RG, Zukle PK. Freshly
harvested cadaveric venous homografts as arterial conduits in infected
fields. Surgery 1987;101:283-91.
18. Di Muzio PJ, Reilly LM, Stoney RJ. Redo aortic grafting after treatment
of aortic graft infection. J Vasc Surg 1996;24:328-37.
19. Kieffer E, Gomes D, Plissonnier D, Koskas F, Bahnini A. Current use of
allografts for infrarenal aortic graft infection. In: Yao JST, Pearce WH,
editors. Modern vascular surgery. New York (NY): McGraw-Hill; 2000.
297-308.20. Koskas F, Plissonnier D, Bahnini A, Ruotolo C, Kieffer E. In situ arterial
allografting for aortoiliac graft infection: a 6-year experience. Cardio-
vasc Surg 1996;4:495-9.
21. Ruotolo C, Plissonnier D, Bahnini A, Koskas F, Kieffer E. In situ arterial
allograft: a new treatment for aortic prosthetic infection. Eur J Vasc
Endovasc Surg 1997;14(suppl A):102-7.
22. Chiesa R, Astore D, Piccolo G, Melissano G, Jannello A, Frigerio D, et
al. Fresh and cryopreserved arterial homografts in the treatment of
prosthetic graft infections: experience of the Italian Collaborative Vas-
cular Homograft Group. Ann Vasc Surg 1998;12:457-62.
23. Desgranges P, Beaujan F, Brunet S, Cavillon A, Qvarfordt P, Mellie`re
D, et al. Cryopreserved arterial allografts used for the treatment of
infected vascular grafts. Ann Vasc Surg 1998;12:583-8.
24. Locati P, Novati C, Socrate AM, Costantini E, Moriacchi E, Piazzal-
unga G, et al. The use of arterial allografts in aortic graft infections: a
three year experience in eighteen patients. J Cardiovasc Surg 1998;39:
735-41.
25. Lehalle B, Geschier C, Fieve G, Stoltz JF. Early rupture and degenera-
tion of cryopreserved arterial allografts. J Vasc Surg 1997;25:751-2.
26. Nevelsteen A, Feryn T, Lacroix H, Suy R, Goffin Y. Experience with
cryopreserved arterial allografts in the treatment of prosthetic graft
infections. Cardiovasc Surg 1998;6:378-83.
27. Noel AA, Gloviczki P, Cherry KJ, Safi H, Goldstone J, Morash MD, et
al. Abdominal aortic reconstruction in infected fields: early results of the
United States Cryopreserved Aortic Allograft Registry. J Vasc Surg
2002;35:847-52.
28. Verhelst R, Lacroix V, Vraux H, Lavigne JP, Vandamme H, Limet R, et
al. Use of cryopreserved arterial homografts for management of infected
prosthetic grafts: a multicentric study. Ann Vasc Surg 2000;14:602-7.
29. Wassenaar C, Wijsmuller EG, Van Herwerden LA, Aghai Z, Van Tricht
CLJ, Bos E. Cracks in cryopreserved aortic allografts and rapid thawing.
Ann Thorac Surg 1995;60:S165-7.
30. Boren CH, Roon AJ, Moore WS. Maintenance of viable arterial allo-
grafts by cryopreservation. Surgery 1978;83:382-91.
31. Motomura N, Imakita M, Yutani C, Takamoto S, Kotoh Y, Tsuji T, et
al. Histologic modification by cryopreservation in rat aortic allografts.
Ann Thorac Surg 1995;60:S168-71.
32. Neves JP, Gulbenkian S, Ramos T, Martins AP, Caldas MC, Mas-
carenhas R, et al. Mechanisms underlying degeneration of cryopre-
served vascular homografts. J Thorac Cardiovasc Surg 1997;113:1014-
21.
33. Vischjager M, Van Gulik TM, Van Marie J, Pfaffendorf M, Jacobs
MJHM. Function of cryopreserved arterial allografts under immuno-
suppressive protection with cyclosporine A. J Vasc Surg 1996;24:876-
82.
34. Camiade C, Goldschmidt P, Koskas F, Ricco J-B, Jarraya M, Gerota J,
et al. Optimization of the resistance of arterial allografts to infection:
comparative study with synthetic prostheses. Ann Vasc Surg 2001;15:
186-96.
35. Knosalla C, Goeau-Brissonnie`re O, Leflon V, Bruneval P, Eugene M,
Pechere JC, et al. Treatment of vascular graft infection by in situ
replacement with cryopreserved aortic allografts: an experimental study.
J Vasc Surg 1998;27:689-98.
36. Koskas F, Goeau-Brissonnie`re O, Nicolas MH, Bacourt F, Kieffer E.
Arteries from human beings are less infectible by Staphylococcus aureus
than polytetrafluoroethylene in an aortic dog model. J Vasc Surg
1996;23:472-6.
37. Lese`che G, Castier Y, Petit MD, Bertrand P, Kitzis M, Mussot S, et al.
Long-term results of cryopreserved arterial allograft reconstruction in
infected prosthetic grafts and mycotic aneurysms of the abdominal
aorta. J Vasc Surg 2001;34:616-22.
38. Petersen MJ, Abbott WM, H’Doubler PB Jr, L’Italien GJ, Hoppel BE,
Rosen BR, et al. Hemodynamics and aneurysm development in vascular
allografts. J Vasc Surg 1993;18:955-64.
39. Plissonnier D, Nochy D, Poncet P, Mandet C, Hinglais N, Bariety J, et
al. Sequential immunological targeting of chronic experimental arterial
allograft. Transplantation 1995;60:414-24.
40. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM.
Immunosuppressive treatment of aortic allografts. J Vasc Surg 1998;7:
82-92.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 5 Kieffer et al 101741. Halpert B, DeBakey ME, Jordan GL, Henly WS. The fate of ho-
mografts and prostheses of the human aorta. Surg Gynecol Obstet
1960;111:659-74.
42. Humphries AW, Hawk WA, De Wolfe VG, LeFevre FA. Clinicopatho-
logic observations on the fate of arterial freeze-dried homografts. Sur-
gery 1959;45:59-71.
43. Knox WG, Miller RE. Long-term appraisal of aortic and arterial
homografts implanted in years 1954-1957. Ann Surg 1970;172:
1076-8.
44. Meade JW, Linton RR, Darling RC, Menendez CV. Arterial ho-
mografts: a long-term clinical follow-up. Arch Surg 1966;93:392-9.
45. Szilagyi DE, McDonald RT, Smith RF, Whitcomb JG. Biologic fate of
human arterial homografts. Arch Surg 1957;75:506-29.
46. Szilagyi DE, Rodriguez FJ, Smith RF, Elliott JP. Late fate of arterial
allografts: observations 6 to 15 years after implantation. Arch Surg
1970;101:721-33.
47. Allaire E, Guettier C, Bruneval P, Plissonnier D, Michel JB. Cell-freearterial grafts: morphologic characteristics of aortic isografts, allografts,
and xenografts in rats. J Vasc Surg 1994;19:446-56.
48. Julia PL, Sapoval M, Diemont F, Chemla E, Gaux JC, Fabiani JN.
Endovascular repair of aortic allograft aneurysmal degeneration: a case
report. J Vasc Surg 2000;32:1222-4.
49. Giglio JS, Ollerenshaw JD, Dawson PE, Black KS, Abbott WM. Cryopreser-
vation prevents arterial allograft dilatation. Ann Vasc Surg 2002;16:762-7.
50. Dumont CE, Plissonnier D, Guettier C, Michel JB. Effects of glutaral-
dehyde on experimental arterial iso and allografts in rats. J Surg Res
1993;54:61-9.
Submitted Jun 6, 2003; accepted Dec 10, 2003.
Available online Mar 15, 2004.
Additional material for this article may be found online
at www.mosby.com/jvs.Receive table of contents by e-mail
To receive the tables of contents by e-mail, sign up through our Web site at
http://www.mosby.com/jvs
Choose E-mail Notification
Simply type your e-mail address in the box and click the Subscribe button
Alternatively, you may send an e-mail message to majordomo@mosby.com
Leave the subject line blank and type the following as the body of your message:
subscribe jvs_toc
You will receive an e-mail to confirm that you have been added to the mailing list.
Note that TOC e-mails will be sent out when a new issue is posted to the Web site.
